Reporte zur Charge 037N21A

Symptomtext

No adverse event; Dose 1 on 23-Mar-2021 and Dose 2 on 15-May-2021 (53 days gap); This spontaneous case was reported by a pharmacist and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Dose 1 on 23-Mar-2021 and Dose 2 on 15-May-2021 (53 days gap)) and NO ADVERSE EVENT (No adverse event) in an 82-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 033H21A, 031B21A and 037N21A) for COVID-19 prophylaxis. No Medical History information was reported. On 23-Mar-2021 at 9:24 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 15-May-2021 at 9:09 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On 25-Jan-2022 at 1:02 PM, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .25 milliliter. On 15-May-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Dose 1 on 23-Mar-2021 and Dose 2 on 15-May-2021 (53 days gap)). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Dose 1 on 23-Mar-2021 and Dose 2 on 15-May-2021 (53 days gap)) and NO ADVERSE EVENT (No adverse event) outcome was unknown. For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Dose 1 on 23-Mar-2021 and Dose 2 on 15-May-2021 (53 days gap)). No concomitant medication were reported. No treatment medication were reported. This case was linked to MOD-2022-693247 (Patient Link).